Physician profile
Thong T Bui
NPI 1073589651
$3,375.05
in general payments reported to CMS, 2019-2025
30 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $218 · 2021: $258 · 2022: $466 · 2023: $616 · 2024: $564 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.13 |
| Education | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $800.51 | 2019-2025 | Xtandi, Myrbetriq |
| 180 Medical, INC. | $345.28 | 2019-2025 | Cure Catheter |
| Abbvie INC. | $309.76 | 2019-2024 | Botox |
| Boston Scientific Corporation | $262.25 | 2019-2025 | Spaceoar Vue System - 10ml, Lithovue Elite, Rezum Generator |
| Pfizer INC. | $247.30 | 2019-2024 | |
| Coloplast Corp | $225.34 | 2019-2021 | |
| Janssen Biotech, INC. | $190.06 | 2019-2025 | Erleada |
| Allergan, INC. | $94.84 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $94.48 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $87.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $81.63 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $70.90 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $67.36 | 2023 | Orgovyx, Gemtesa |
| Amgen INC. | $53.24 | 2020-2023 | Xgeva |
| Travere Therapeutics, INC. | $47.97 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $41.41 | 2022 | |
| Myovant Sciences INC. | $41.34 | 2022 | |
| Ambu INC. | $31.54 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $30.46 | 2025 | |
| Teleflex LLC | $29.76 | 2024 | |
| Cook Medical LLC | $27.50 | 2020 | |
| Urovant Sciences INC | $26.14 | 2022 | |
| Histosonics, INC. | $25.64 | 2025 | |
| Dendreon Pharmaceuticals LLC | $25.59 | 2019 | |
| Tolmar, INC. | $25.46 | 2025 | Eligard, Jatenzo |
| Immunitybio, INC. | $19.29 | 2024 | |
| Urogen Pharma, INC. | $19.03 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.88 | 2023 | Oxlumo |
| Endo USA, INC. | $18.84 | 2025 | Aveed, Xiaflex |
| Baxter Healthcare | $15.41 | 2023 | Tisseel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thong Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.